MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.
3 reports, 2 independent
Updated Sep 22
No new developments lately
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MIaMI was mentioned in connection with Naarden, Netherlands, while Menarini submitted an MAA for obicetrapib and partnered with NewAmsterdam.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
MIaMI
Czech company
-
Netherlands
one of the four autonomous countries of the Kingdom of the Netherlands; with territories in the Caribbean
-
Menarini
Italian pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- themarketsdaily.com
- GlobeNewswireNewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib -- Filings both for the obicetrapib monotherapy and obicetrapib plus e